Human MASP-2 Inhibitors Resolving Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for the lectin pathway of the complement system, such as SFTI-based and Pacifastin-based compounds, are non-human in origin, posing a significant risk of immunogenicity in humans and lacking specificity in inhibiting the MASP-2 enzyme.
Innovation Solution
Development of human protein-based MASP-2 inhibitors with specific amino acid sequences, particularly using the Kunitz domain of the human Tissue Factor Pathway Inhibitor-1 protein, to selectively target and inhibit the MASP-2 enzyme, thereby reducing the risk of immunogenicity and improving specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-human protein-based inhibitors (SFTI-based, Pacifastin-based) are used to inhibit the lectin pathway, then inhibitory activity is achieved, but immunogenicity risk increases and specificity for MASP-2 is reduced
Solution Approach 1:
The invention changes the fundamental parameter of protein origin from non-human to human. By using human Tissue Factor Pathway Inhibitor-1 (TFPI-1) as the scaffold and modifying its amino acid sequence, the inhibitor achieves both high MASP-2 specificity and low immunogenicity, as the human protein structure is recognized as self by the human immune system
Solution Approach 2:
The invention creates a humanized version of the inhibitor by copying the functional principles of natural human proteins (TFPI-1) and adapting them to target MASP-2. The human protein sequence serves as a template that is modified to achieve specific inhibition while maintaining biocompatibility
2Reliability
If non-human protein-based inhibitors are used, then complement system modulation is achieved, but specificity for MASP-2 enzyme is reduced
Solution Approach 1:
The invention applies local quality by making specific, targeted modifications to the TFPI-1 protein sequence at key positions (P1, P2, P4) that directly interact with MASP-2. These localized changes enhance binding specificity to MASP-2 while the rest of the human protein structure remains intact, ensuring biocompatibility
Solution Approach 2:
The inhibitor design segments the protein into a human scaffold (TFPI-1 backbone providing biocompatibility) and a modified inhibitory loop (providing MASP-2 specificity). This segmentation allows independent optimization of both safety and efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The human protein-based MASP-2 inhibitors effectively and selectively inhibit the MASP-2 enzyme, providing a safer and more targeted approach to modulating the complement system, potentially treating conditions like ischemia-reperfusion injuries and autoimmune diseases without triggering general immunosuppression.
Implementation Method 1
The human protein-based MASP-2 inhibitors effectively and selectively inhibit the MASP-2 enzyme, providing a safer and more targeted approach to modulating the complement system
Data Source
AI summary
The invention relates to proteins containing any of the sequences according to general formula (Ih):X1CRX2X3X4X5 (Ih)whereX1 is F, Y, L, P, Q, M, V, W, A, T andX2 is A, G, S, T andX3 is V, A, I, L, M, D, H, S andX4 is K, I, Q, R, H, S, F, M, N, L, V andX5 is R, V, I, K, M, Q, E, F, L, N, Y, D, S, H. andits salts, esters and pharmaceutically acceptable prodrugs. The invention further relates to pharmaceutical preparations and kits containing said proteins, to screening procedures using said proteins. The proteins of the invention are useful in the treatment or prevention of diseases that can be treated by inhibiting the complement system.